## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.00 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($223.85)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Humana Inc. (HUM) Investigation: Bronstein, Gewirtz & Grossman, L**
- Source: The National Law Review | 20251130T043621 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. (NYSE:HUM) securities. This investigation follows a U.S. Department of Justice complaint alleging that Humana engaged in illegal kickbacks to brokers for Medicare Advantage enrollments, which led to a drop in Humana's stock price. Investors are encouraged to contact the law firm to learn more about the investigation.

**2. Humana (NYSE: HUM) reiterates FY 2025 GAAP EPS $12.26 and adjusted EPS $17.00**
- Source: Stock Titan | 20251201T073000 | Neutral | Relevance: 99%
- Humana Inc. is reaffirming its full-year 2025 profit outlook, projecting approximately $12.26 in GAAP diluted earnings per share (EPS) and approximately $17.00 in adjusted (non-GAAP) EPS. This guidance remains consistent with previous statements and is being reiterated by senior management during investor and analyst meetings in December 2025. The company uses adjusted EPS to better analyze core operating performance, noting that while GAAP EPS may see future changes, adjusted EPS guidance is expected to remain stable.

**3. Ceredex Value Advisors LLC Acquires Shares of 71,650 Humana Inc. $HUM**
- Source: MarketBeat | 20251129T092121 | Somewhat-Bullish | Relevance: 99%
- Ceredex Value Advisors LLC acquired a new stake of 71,650 shares in Humana Inc. (NYSE:HUM) during the second quarter, valued at approximately $17.52 million and representing 0.06% ownership. Humana recently beat Q3 earnings estimates with $3.24 EPS on $32.65 billion revenue, also declaring a quarterly dividend of $0.885 per share. The stock has a market capitalization of $29.55 billion and a P/E ratio of 18.86, with institutional investors owning 92.38% of the company.

**4. Crake Asset Management LLP Makes New Investment in Humana Inc. $HUM**
- Source: MarketBeat | 20251129T132137 | Somewhat-Bullish | Relevance: 99%
- Crake Asset Management LLP has made a significant new investment in Humana Inc. by acquiring 166,950 shares valued at approximately $40.82 million in Q2, making up 2.2% of Crake's portfolio. This investment comes as Humana reported strong Q3 earnings, beating analyst estimates, and declared a quarterly dividend. The article also details recent analyst ratings and other institutional investment activities in Humana stock.

**5. Humana Inc. $HUM Shares Bought by Quadrature Capital Ltd**
- Source: MarketBeat | 20251129T125112 | Somewhat-Bullish | Relevance: 99%
- Quadrature Capital Ltd significantly increased its stake in Humana Inc. by 571.9% in Q2, acquiring an additional 56,695 shares for a total holding of 66,609 shares valued at approximately $16.28 million. This increase ininstitutional investment comes as Humana reported strong quarterly earnings, beating analyst estimates with an EPS of $3.24 and revenue of $32.65 billion, an 11.1% increase year-over-year. Despite mixed analyst sentiment, with a consensus "Hold" rating, the company also announced a quarterly dividend of $0.885 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Jefferies | $313 | $253 | +24% |
| 2025-11-25 | Barclays | $234 | $245 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Jefferies | up | Buy |
| 2025-11-25 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Long-term trend broken: trading 6.4% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Balance sheet: strong liquidity (2.0x). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $30.9B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 19.2 |
| Current P/E | 14.2 |
| YoY Growth | -26.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -8.1% to -1.6% (+6.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.6pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Below SMA200 (0.94x), long-term trend not supportive. MACD histogram positive (1.82), confirming momentum. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.59% (CS: 32) | Neutral |
| RSI_14 | 44.2 | Neutral |
| MACD Histogram | 1.82 | Bullish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 0.921x | Below |
| vs SMA200 | 0.936x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $242.23
- **Stop Loss:** $223.85 (7.6% risk)
- **Target:** $278.99 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 40
- **Position Value:** $9,689.20
- **Portfolio %:** 9.69%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*